Kiran Mazumdar-Shaw: Biosimilars Are Biocon's Weapon Against Unaffordable Biologics

The Biocon founder's 'affordable innovation' philosophy drives a biosimilar portfolio spanning insulin to oncology biologics, with Mylan/Viatris partnership targeting US and EU regulated markets.

bt-corporate · 7/19/2026, 6:46:09 AM · Ask about this →